Chondroitin Sulfate

Chondroitin sulfate is a sulfated glycosaminoglycan and a major structural component of cartilage, where long chains attached to aggrecan create the fixed negative charge that draws in water and gives cartilage its compressive resilience. That structural role made it an obvious candidate for osteoarthritis, and it has been studied extensively — with results that genuinely divide expert opinion.

The negative case is strong. The NIH-funded GAIT trial randomised 1583 patients and found chondroitin alone no better than placebo for knee pain overall, though a prespecified subgroup with moderate-to-severe pain improved. Several meta-analyses report effect sizes so small as to be clinically meaningless, and note that trial quality inversely predicts reported benefit.

The positive case is more specific than it first appears. European trials using pharmaceutical-grade chondroitin sulfate — a regulated prescription product in several countries, with verified molecular weight and purity — show modest pain improvement and, more interestingly, reduced radiographic joint space narrowing over two years, suggesting a structure-modifying rather than merely analgesic effect. A 2017 trial found prescription chondroitin non-inferior to celecoxib. Mechanistically it inhibits matrix metalloproteinases and aggrecanases, reduces NF-kB signalling in chondrocytes, and stimulates hyaluronan production by synoviocytes.

Product quality is the practical crux. Analyses have repeatedly found retail chondroitin products containing far less than labelled, sometimes near zero, with cheaper glycosaminoglycans substituted. Bovine and porcine sources differ in molecular weight and sulfation pattern from shark-derived material. If you trial it, buy a verified product, combine it with glucosamine as most positive trials did, give it three months, and stop if nothing changes.